Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
Home > Apraclonidine 0.125% maintains ocular redness reduction over 8 weeks

Apraclonidine 0.125% maintains ocular redness reduction over 8 weeks

Optometry 360

Key Takeaways

  1. Ocular redness was significantly reduced within 1 minute and remained reduced through 12 hours.
  2. Ocular redness was significantly reduced within 1 minute and remained reduced through 12 hours.

Apraclonidine hydrochloride (HCl) ophthalmic solution 0.125% rapidly reduced ocular redness for up to 12 hours without evidence of tachyphylaxis over 8 weeks in adults with nonspecific ocular redness, according to a presentation at Academy 2026 Anaheim.

The double-masked, vehicle-controlled clinical trial included 125 adults with baseline ocular redness scores ≥1 on the Ora Calibra Ocular Hyperemia Scale. Participants were randomized to apraclonidine HCl 0.125% or vehicle. Patients received doses twice daily from Days 2 through 55.

Compared with vehicle, apraclonidine produced greater reductions in ocular redness at both 15 minutes and 10 hours on Day 1, with differences of 1.60 and 1.00 units, respectively (both P < 0.0001). Significant reductions were also observed at time points from 1 minute through 12 hours, demonstrating rapid onset and sustained effect.

Reductions in redness were maintained at Days 14, 28, and 56. There was no evidence of tachyphylaxis. Rebound redness after treatment discontinuation was low in both groups. No treatment-related serious adverse events were reported, and adverse events were infrequent and predominantly mild. Overall, apraclonidine HCl 0.125% was well tolerated.

Reference

Vedamurthy I and Nakagawara E. Clinical Efficacy and Safety of Apraclonidine HCl 0.125% for Ocular Redness in Adults: A Phase 3 Study. Presented at: American Academy of Optometry (Academy 2026); September 30-October 3, 2026; Anaheim, CA.

Related Content